PMGC Holdings Inc. logo

PMGC Holdings Inc.(ELAB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.58
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ELAB

11/13/2026: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.

PMGC Holdings Inc. is a micro-cap life sciences and holding company that develops proprietary exosome-based skincare formulations alongside clinical-stage metabolic and obesity therapeutics. The company's main business strength lies in its innovative exosome technology platform and expansion into high-demand anti-obesity pipelines. Its primary growth opportunity centers on advancing therapeutic candidates like EL-32 and scaling its physician-dispensed product lines. However, the company faces substantial risks including intense biopharmaceutical competition, micro-cap price volatility, and ongoing net operating losses. It represents a speculative fit primarily for risk-tolerant growth or momentum investors who should closely monitor clinical trial progress and capital-raising updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in high-growth sectors, the company's micro-cap scale introduces high operational uncertainty.
Momentum investorStrong fit while signal remains positiveLow market capitalization can occasionally trigger sharp short-term price movements upon clinical or corporate news.
Value investorWeak fitOngoing net losses and lack of stable earnings make traditional fundamental valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends, focusing entirely on cash preservation and growth.
Low-risk investorWeak fitHigh price volatility, micro-cap liquidity risks, and early-stage execution hurdles present substantial risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and low daily trading volumes frequently lead to exaggerated price swings.
Valuation riskHighTraditional valuation metrics are difficult to apply given minimal early-stage revenues and net losses.
Competition risk (biopharmaceutical and aesthetics competition)HighThe company competes against dominant multi-national corporations with massive commercial scale.
Business qualityMediumProprietary exosome technology shows promise, but early-stage operations lack proven multi-product scale.
Dividend incomeLow / noneNo payouts are provided to shareholders.
Execution riskHighSuccessful clinical advancement of metabolic therapies and commercial scaling are execution-dependent.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.28M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 477.0K shares
Beta -0.27
52 Weeks Range 1.41 - 1344.00
Updated Date 11/15/2026
52 Weeks Range 1.41 - 1344.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1748.36

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ELAB receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft analyst coverage.

Company Fundamentals

★★★★★
ELAB has soft overall fundamentals (2 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-23.4%), weak cash generation (FCF margin -1081.6%), negative revenue growth (-76.1%).

Financial Health Rating

★★★★★
ELAB's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 22.8%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
ELAB's growth profile is soft, with the least-weak measure being free-cash-flow growth at -16.1% FY2025 versus FY2024. By comparison, while revenue growth (-76.1%, negative) and earnings growth (-23.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 2.8% (soft) and 94.4% of outstanding shares are publicly tradable (strong). Insider ownership of 5.71% supports management-shareholder alignment.

Top 5 Institutional Investors

Jane Street Group LLC 1.01%
Morgan Stanley - Brokerage Accounts 0.65%
Vanguard Fiduciary Trust Co 0.42%
Geode Capital Management, LLC 0.30%
Vanguard Capital Management, LLC 0.21%

Unit Economics (Per $1K Revenue)

★★★★★
ELAB generates approximately $127 of gross profit, $-12,501 of operating income, and $-10,816 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.54%

Quantitative Style Profile

★★★★★
ELAB has a liquid, relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Medical Aesthetics & SkincareSales of physician-dispensed topical skincare formulations containing Elevai Exosomes.Provides the primary baseline of commercial product revenue through clinic networks.
Strategic Holdings & InvestmentsEquity stakes, debentures, and financial instruments in emerging technology and energy sectors.Acts as an auxiliary driver of asset value outside core life science operations.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3.29M
Price to Sales(TTM) 0.5
Enterprise Value -3.29M
Price to Sales(TTM) 0.5
Enterprise Value to Revenue 0.06
Enterprise Value to EBITDA -
Shares Outstanding 809.58K
Shares Floating 764.19K
Shares Outstanding 809.58K
Shares Floating 764.19K
Percent Insiders 5.71
Percent Institutions 2.81

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.